Sign in
CompletedPhase 4

Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

Key facts

Who runs it
Centers for Disease Control and Prevention
Where
Houston, Salt Lake City, Tallahassee, and Tucson, United StatesSee the 4 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
3,988 people enrolled
Started
13 Sept 2022
Ended
31 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Fluzone Quadrivalent
  • Flublok Quadrivalent
Record updated
30 July 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Aged 18-64 years
  • Comfortable reading and responding to text messages or emails sent in either English, Spanish, or Chinese
  • Currently enrolled as a student in a college or graduate degree program AND attending in-person classes with other students; OR Currently employed as a frontline worker defined as an occupation that cannot be done from home or alone AND have direct face-to-face contact, defined as being within 6 feet, or about two arms' lengths, with co-workers, patients or the public as part of full-time (at least 20 hours per week) job responsibilities
  • Have daily access to the internet and a mobile phone that can send and receive text messages
  • Plan to continue to live/work in the study area through May 2023 (if trial season 1) or May 2024 (if trial season 2). For students in college or graduate degree programs, this is defined as living/working in the area excluding brief absences during school vacation periods

Who cannot take part

  • Previous hypersensitivity reaction to the study vaccines as reported by the subject
  • Has already received current year influenza vaccine on our after July 1, 2022 as reported by the subject
  • Lives with another person who is already enrolled in this study as reported by the subject

Where in United States

  • Baylor College of MedicineHouston, United States
  • University of UtahSalt Lake City, United States
  • Florida A&M UniversityTallahassee, United States
  • University of ArizonaTucson, United States

About the trial

What the trial wants to find out

This randomized, active comparator trial will compare the clinical efficacy of recombinant influenza vaccine (RIV) to standard-dose egg-based inactivated influenza vaccine (SD IIV) among adults aged 18-64 years. The primary study hypothesis is that the clinical efficacy of RIV is superior to that of SD IIV to prevent and attenuate influenza-like illness (ILI)-associated influenza virus infection. Relative efficacy will be assessed by comparing rates of ILI-associated reverse transcription polymerase chain reaction (RT-PCR)-confirmed influenza virus infection and measures of infection and illness attenuation among participants who receive RIV versus SD IIV. A secondary hypothesis is that humoral and cell-mediated immune responses to RIV are superior to responses to SD IIV. Relative immunogenicity will be assessed by comparing markers of humoral and cell-mediated immune responses post-vaccination among a subset of participants who receive RIV versus SD IIV.

The 2 groups in the trial

  • Recombinant Influenza Vaccine (RIV)Existing treatment, for comparison

    recombinant vaccine Flublok® Quadrivalent

    Treatment: Flublok Quadrivalent

  • Standard-Dose Inactivate Influenza Vaccine (SD IIV)Existing treatment, for comparison

    egg-based vaccines Fluzone® Quadrivalent or Fluarix® Quadrivalent at approximately 28 days after receipt of the 2018-19 and 2019-20 vaccines

    Treatment: Fluzone Quadrivalent

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Participant- and Investigator-Blinded Trial to Compare the Clinical Efficacy of Recombinant Influenza Vaccine to Standard Dose Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years in the United States
Publications
Record updated
30 July 2026